Trump Demands Fed's Lisa Cook Quit
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
NVDA: Top Analysts Lift Nvidia Targets Ahead of Earnings -- Can AI Boom Deliver?
This article first appeared on GuruFocus. Aug 21 - Nvidia (NASDAQ:NVDA) continues to draw investor attention as analysts raise their price targets ahead of the company's second-quarter earnings report on August 27. The chipmaker's stock outlook remains supported by strong AI demand, its leadership position in the semiconductor market, and easing U.S. export restrictions. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Is NVDA fairly valued? Test your thesis with our free DCF calculator. Shares of NVDA edged higher on Thursday's opening. Consensus estimates call for earnings of $1.01 per share on revenue of $45.87 billion. Analysts remain confident that Nvidia will deliver another solid quarter, although expectations are high. KeyBanc analyst John Vinh increased his price target on NVDA to $215 from $190 while reiterating a Buy rating. Vinh expects strong July-quarter results but noted guidance for the October quarter could be more cautious, as forecasts likely exclude China sales pending license approvals. If those sales are included, Nvidia could generate an additional $2 billion to $3 billion from its H20 and RTX6000D chips. Susquehanna analyst Christopher Rolland also lifted his target, moving to $210 from $180 with a Buy rating. Rolland cited the strength of Nvidia's data center segment and highlighted the upcoming GB300 product line as a catalyst for double-digit revenue growth, supported by higher selling prices and expanding margins. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
All The People Who Work At Palantir Technologies Inc. (PLTR) Are 'Geniuses,' Says Jim Cramer
We recently published . Palantir Technologies Inc. (NASDAQ:PLTR) is one of the stocks Jim Cramer recently discussed. Palantir Technologies Inc. (NASDAQ:PLTR) is a data analytics company whose shares have run into a bit of trouble recently. They have lost a whopping 16.6% over the past five days to underscore the inherent volatility in shares, which trade at 500x earnings. Cramer has been one of the first to predict Palantir Technologies Inc. (NASDAQ:PLTR)'s strong performance and has praised the firm for its earnings performance. These comments were made just as the dip started, and Cramer discussed a piece by Citron Research outlining that Palantir Technologies Inc. (NASDAQ:PLTR) was worth $40 considering OpenAI's $500 billion valuation: '[On a Citron piece] David, Palantir? You want to get in the way of that juggernaut? The only people who short that . . .and they don't even know. One guy called me and he goes, listen man, I'm shorting this stock, I don't know if you know it. Plantir! Plantir! The CNBC TV host praised Palantir Technologies Inc. (NASDAQ:PLTR) after its earnings. Here is what he said: 'Palantir Technology reported a spectacular quarter after the close, much better than expected revenue, up 48% year-over-year, 2 cent earnings beat off a 14 cent basis, management raising their full year forecast dramatically. Company's Rule of 40 score, which combines the revenue growth rate with the adjusted operating margin, came in at 94 for the quarter. I've never seen anything like it, so no wonder this already red-hot stock could surge in after-hours trading. While we acknowledge the potential of PLTR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
US-EU trade deal impacts on pharma industry more 'manageable' than expected
A 15% import tariff on pharmaceutical goods from the European Union to the US is going to have a lesser impact on the pharmaceutical industry than Wall Street feared. Big pharmaceutical stocks like Pfizer (PFE), Eli Lilly (LLY), and Johnson & Johnson (JNJ) rose slightly, by about 1%, in trading Thursday after the trade deal was announced, putting to rest concerns of tariffs threatened as high as 200% previously by President Trump. "The two regions have established a 15% tariff cap on imported drugs from EU to the US. This is being viewed by most as both manageable and below the 20%+ rate many expected," wrote Mizuho's healthcare expert Jared Holz in a note to clients Thursday. The deal outlined by the US and EU has multiple parts that impact the pharmaceutical industry, with some clarity still needed. The first is levying either the 15% tariff or the Most Favored Nation (MFN) pricing, whichever is higher, on pharma drugs manufactured in the EU. This puts more emphasis on President Trump's efforts to equalize US drug costs to the lower prices seen in the EU and other developed nations and also impacts a smaller portion of products, as pharma executives have emphasized that most of the branded drugs sold in the US are made in the US. But questions remain on whether the finalize products, or some components, will be taxed. "The United States commits to apply the higher of either the US MFN tariff rate or a tariff rate of 15 percent, comprised of the MFN tariff and a reciprocal tariff, on originating goods of the European Union," according to the White House statement. The second part of the deal is that, as of Sept. 1, the US will enforce MFN pricing on generics and "chemical precursors." The latter refers to active pharmaceutical ingredients, which are the key chemical compounds in any drug. They are cheaper to mass-produce overseas, largely in Asia or Ireland. Experts say that prices for generics, which account for a majority of prescriptions filled in the US, are already low. "The administration is, for the time being, focusing Most Favored Nations pricing on generic products — hoping to peg US prices to that of other countries. Given the already lower cost of generic medicines and net price paid domestically, see the financial ramifications here as more limited than not. Have to look deeper at what precise drugs will be subject to this regulation but for now, not a strategy we see as stifling the industry/major players," Mizuho's Holz said. Its why big generics players, like Teva (TEVA), saw their stocks also rise on the news — up more than 4% Thursday. UBS analyst Ashwani Verma called the trade deal a positive for drugmakers, in a note to clients Thursday. The deal also left wiggle room for additional items: "The United States and the European Union agree to consider other sectors and products that are important for their economies and value chains for inclusion in the list of products for which only the MFN tariffs would apply," according to the White House statement. J.P. Morgan analyst Chris Schott told clients Thursday that clarity on details — including which components are chosen and how the tariffs are levied — as well as the pending results of an investigation by the US Department of Commerce Bureau of Industry and Security, will determine the final impact. In addition, Schott noted that many companies have already stocked up on products in advance of the expected tariff deal, and have inventory through mid-2026. "In the near-term, we see inventory stocking as largely limiting the impact of tariffs through mid-to-late 2026 or longer in some cases," Schott said. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
